View in EDS

Pan-RAF inhibitor exarafenib targets BRAF class II/III NSCLC and reveals ARAF-KSR1 resistance and combination strategies.

Saved in:
Bibliographic Details
Title: Pan-RAF inhibitor exarafenib targets BRAF class II/III NSCLC and reveals ARAF-KSR1 resistance and combination strategies.
Authors: Manabe T; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA. tadashi.manabe@ucsf.edu.; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA. tadashi.manabe@ucsf.edu.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA. tadashi.manabe@ucsf.edu., Bergo HC; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA., Li Q; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA., Wang TS; Kinnate Biopharma, San Diego, CA, USA., Severson P; Kinnate Biopharma, San Diego, CA, USA., Miller N; Kinnate Biopharma, San Diego, CA, USA., Lee C; Kinnate Biopharma, San Diego, CA, USA., Yay Donderici E; Guardant Health, Redwood City, CA, USA., Zhang N; Guardant Health, Redwood City, CA, USA., Wu W; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA., Chou YT; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA., Kerr DL; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA., Allegakoen P; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA., Grandinetti KB; Kinnate Biopharma, San Diego, CA, USA., Soroceanu L; Kinnate Biopharma, San Diego, CA, USA., Pelham RJ; Kinnate Biopharma, San Diego, CA, USA., Martin ES; Kinnate Biopharma, San Diego, CA, USA., Murphy EA; Kinnate Biopharma, San Diego, CA, USA., Khanna V; Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA., Neal JW; Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA., Chen CT; Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA., Kato S; Division of Hematology and Oncology, University of California San Diego, Moores Cancer Center, La Jolla, CA, USA., Williams R; Kinnate Biopharma, San Diego, CA, USA., Bivona TG; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA. trever.bivona@ucsf.edu.; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA. trever.bivona@ucsf.edu.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA. trever.bivona@ucsf.edu.; Chan-Zuckerberg Biohub, San Francisco, CA, USA. trever.bivona@ucsf.edu.
Source: Nature communications [Nat Commun] 2026 Feb 07; Vol. 17 (1). Date of Electronic Publication: 2026 Feb 07.
Publication Type: Journal Article
Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41654519
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Pan-RAF inhibitor exarafenib targets BRAF class II/III NSCLC and reveals ARAF-KSR1 resistance and combination strategies.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Manabe+T%22">Manabe T</searchLink>; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA. tadashi.manabe@ucsf.edu.; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA. tadashi.manabe@ucsf.edu.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA. tadashi.manabe@ucsf.edu.<br /><searchLink fieldCode="AU" term="%22Bergo+HC%22">Bergo HC</searchLink>; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Li+Q%22">Li Q</searchLink>; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Wang+TS%22">Wang TS</searchLink>; Kinnate Biopharma, San Diego, CA, USA.<br /><searchLink fieldCode="AU" term="%22Severson+P%22">Severson P</searchLink>; Kinnate Biopharma, San Diego, CA, USA.<br /><searchLink fieldCode="AU" term="%22Miller+N%22">Miller N</searchLink>; Kinnate Biopharma, San Diego, CA, USA.<br /><searchLink fieldCode="AU" term="%22Lee+C%22">Lee C</searchLink>; Kinnate Biopharma, San Diego, CA, USA.<br /><searchLink fieldCode="AU" term="%22Yay+Donderici+E%22">Yay Donderici E</searchLink>; Guardant Health, Redwood City, CA, USA.<br /><searchLink fieldCode="AU" term="%22Zhang+N%22">Zhang N</searchLink>; Guardant Health, Redwood City, CA, USA.<br /><searchLink fieldCode="AU" term="%22Wu+W%22">Wu W</searchLink>; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Chou+YT%22">Chou YT</searchLink>; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Kerr+DL%22">Kerr DL</searchLink>; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Allegakoen+P%22">Allegakoen P</searchLink>; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Grandinetti+KB%22">Grandinetti KB</searchLink>; Kinnate Biopharma, San Diego, CA, USA.<br /><searchLink fieldCode="AU" term="%22Soroceanu+L%22">Soroceanu L</searchLink>; Kinnate Biopharma, San Diego, CA, USA.<br /><searchLink fieldCode="AU" term="%22Pelham+RJ%22">Pelham RJ</searchLink>; Kinnate Biopharma, San Diego, CA, USA.<br /><searchLink fieldCode="AU" term="%22Martin+ES%22">Martin ES</searchLink>; Kinnate Biopharma, San Diego, CA, USA.<br /><searchLink fieldCode="AU" term="%22Murphy+EA%22">Murphy EA</searchLink>; Kinnate Biopharma, San Diego, CA, USA.<br /><searchLink fieldCode="AU" term="%22Khanna+V%22">Khanna V</searchLink>; Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.<br /><searchLink fieldCode="AU" term="%22Neal+JW%22">Neal JW</searchLink>; Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.<br /><searchLink fieldCode="AU" term="%22Chen+CT%22">Chen CT</searchLink>; Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.<br /><searchLink fieldCode="AU" term="%22Kato+S%22">Kato S</searchLink>; Division of Hematology and Oncology, University of California San Diego, Moores Cancer Center, La Jolla, CA, USA.<br /><searchLink fieldCode="AU" term="%22Williams+R%22">Williams R</searchLink>; Kinnate Biopharma, San Diego, CA, USA.<br /><searchLink fieldCode="AU" term="%22Bivona+TG%22">Bivona TG</searchLink>; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA. trever.bivona@ucsf.edu.; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA. trever.bivona@ucsf.edu.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA. trever.bivona@ucsf.edu.; Chan-Zuckerberg Biohub, San Francisco, CA, USA. trever.bivona@ucsf.edu.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101528555%22">Nature communications</searchLink> [Nat Commun] 2026 Feb 07; Vol. 17 (1). <i>Date of Electronic Publication: </i>2026 Feb 07.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Pub%2E+Group%22">Nature Pub. Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101528555 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2041-1723 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220411723%22">20411723 </searchLink><i>NLM ISO Abbreviation: </i>Nat Commun <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41654519
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41467-026-69216-3
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: Pan-RAF inhibitor exarafenib targets BRAF class II/III NSCLC and reveals ARAF-KSR1 resistance and combination strategies.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Manabe T
      – PersonEntity:
          Name:
            NameFull: Bergo HC
      – PersonEntity:
          Name:
            NameFull: Li Q
      – PersonEntity:
          Name:
            NameFull: Wang TS
      – PersonEntity:
          Name:
            NameFull: Severson P
      – PersonEntity:
          Name:
            NameFull: Miller N
      – PersonEntity:
          Name:
            NameFull: Lee C
      – PersonEntity:
          Name:
            NameFull: Yay Donderici E
      – PersonEntity:
          Name:
            NameFull: Zhang N
      – PersonEntity:
          Name:
            NameFull: Wu W
      – PersonEntity:
          Name:
            NameFull: Chou YT
      – PersonEntity:
          Name:
            NameFull: Kerr DL
      – PersonEntity:
          Name:
            NameFull: Allegakoen P
      – PersonEntity:
          Name:
            NameFull: Grandinetti KB
      – PersonEntity:
          Name:
            NameFull: Soroceanu L
      – PersonEntity:
          Name:
            NameFull: Pelham RJ
      – PersonEntity:
          Name:
            NameFull: Martin ES
      – PersonEntity:
          Name:
            NameFull: Murphy EA
      – PersonEntity:
          Name:
            NameFull: Khanna V
      – PersonEntity:
          Name:
            NameFull: Neal JW
      – PersonEntity:
          Name:
            NameFull: Chen CT
      – PersonEntity:
          Name:
            NameFull: Kato S
      – PersonEntity:
          Name:
            NameFull: Williams R
      – PersonEntity:
          Name:
            NameFull: Bivona TG
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 07
              M: 02
              Text: 2026 Feb 07
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 2041-1723
          Numbering:
            – Type: volume
              Value: 17
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Nature communications
              Type: main
ResultId 1